Latest Temozolomide Stories
SAN DIEGO, June 7, 2011 /PRNewswire/ -- Tocagen Inc.
CHICAGO, June 6, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant.
Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.
RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.
A new treatment regimen for patients with metastatic colon cancer appears to offer clinical benefit even when used after multiple other treatments have failed.
WASHINGTON, March 17, 2011 /PRNewswire/ -- Novocure announced today that the U.S.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer.
A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.